Hyperlipoproteinemia Type II
"Hyperlipoproteinemia Type II" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins).
| Descriptor ID |
D006938
|
| MeSH Number(s) |
C16.320.565.398.481 C18.452.584.500.500.644.475 C18.452.648.398.481
|
| Concept/Terms |
Hyperlipoproteinemia Type II- Hyperlipoproteinemia Type II
- Hyperlipoproteinemia Type IIs
- Hyper-Low Density Lipoproteinemia
- Density Lipoproteinemia, Hyper-Low
- Density Lipoproteinemias, Hyper-Low
- Hyper Low Density Lipoproteinemia
- Hyper-Low Density Lipoproteinemias
- Lipoproteinemia, Hyper-Low Density
- Lipoproteinemias, Hyper-Low Density
- Hyper-Low-Density-Lipoproteinemia
- Hyper-Low-Density-Lipoproteinemias
- Hyperlipoproteinemia, Type II
- Hyperlipoproteinemias, Type II
- Type II Hyperlipoproteinemia
- Type II Hyperlipoproteinemias
- Hypercholesterolemia, Essential
- Essential Hypercholesterolemia
- Essential Hypercholesterolemias
- Hypercholesterolemias, Essential
- Hypercholesterolemia, Familial
- Familial Hypercholesterolemia
- Familial Hypercholesterolemias
- Hypercholesterolemias, Familial
- Hypercholesterolemic Xanthomatosis, Familial
- Familial Hypercholesterolemic Xanthomatoses
- Familial Hypercholesterolemic Xanthomatosis
- Hypercholesterolemic Xanthomatoses, Familial
- Xanthomatoses, Familial Hypercholesterolemic
- Xanthomatosis, Familial Hypercholesterolemic
- Hyperlipoproteinemia Type 2
- Hyperlipoproteinemia Type 2s
- Type 2, Hyperlipoproteinemia
- Hyper-beta-Lipoproteinemia
- Hyper beta Lipoproteinemia
- Hyper-beta-Lipoproteinemias
- Hyperbetalipoproteinemia
- Hyperbetalipoproteinemias
Hyperlipoproteinemia Type IIb- Hyperlipoproteinemia Type IIb
- Hyperlipoproteinemia Type IIbs
- Hypercholesterolemia, Autosomal Dominant, Type B
- Familial Combined Hyperlipoproteinemia
- Combined Hyperlipoproteinemia, Familial
- Combined Hyperlipoproteinemias, Familial
- Familial Combined Hyperlipoproteinemias
- Hyperlipoproteinemia, Familial Combined
- Hyperlipoproteinemias, Familial Combined
- Apolipoprotein B-100, Familial Defective
- Apolipoprotein B 100, Familial Defective
- Apolipoprotein B-100, Familial Ligand-Defective
- Apolipoprotein B 100, Familial Ligand Defective
Hyperlipoproteinemia Type IIa- Hyperlipoproteinemia Type IIa
- Hyperlipoproteinemia Type IIas
- Hyperlipoproteinemia, Type IIa
- Hyperlipoproteinemias, Type IIa
- Type IIa Hyperlipoproteinemia
- Type IIa Hyperlipoproteinemias
- Hypercholesterolemia, Autosomal Dominant
- Autosomal Dominant Hypercholesterolemia
- Autosomal Dominant Hypercholesterolemias
- Dominant Hypercholesterolemia, Autosomal
- Dominant Hypercholesterolemias, Autosomal
- Hypercholesterolemias, Autosomal Dominant
- LDL Receptor Disorder
- Disorder, LDL Receptor
- Disorders, LDL Receptor
- LDL Receptor Disorders
- Receptor Disorder, LDL
- Receptor Disorders, LDL
|
Below are MeSH descriptors whose meaning is more general than "Hyperlipoproteinemia Type II".
Below are MeSH descriptors whose meaning is more specific than "Hyperlipoproteinemia Type II".
This graph shows the total number of publications written about "Hyperlipoproteinemia Type II" by people in this website by year, and whether "Hyperlipoproteinemia Type II" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 0 | 2 |
| 1997 | 3 | 0 | 3 |
| 1998 | 3 | 0 | 3 |
| 1999 | 3 | 0 | 3 |
| 2000 | 4 | 0 | 4 |
| 2001 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 4 | 0 | 4 |
| 2013 | 5 | 0 | 5 |
| 2014 | 6 | 0 | 6 |
| 2015 | 6 | 0 | 6 |
| 2016 | 5 | 0 | 5 |
| 2017 | 5 | 0 | 5 |
| 2018 | 7 | 0 | 7 |
| 2019 | 4 | 0 | 4 |
| 2020 | 6 | 0 | 6 |
| 2021 | 8 | 0 | 8 |
| 2022 | 4 | 0 | 4 |
| 2023 | 4 | 0 | 4 |
| 2024 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hyperlipoproteinemia Type II" by people in Profiles.
-
Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy. Eur Heart J. 2024 Jul 12; 45(27):2422-2434.
-
Cardiovascular outcomes in patients with homozygous familial hypercholesterolaemia on lipoprotein apheresis initiated during childhood: long-term follow-up of an international cohort from two registries. Lancet Child Adolesc Health. 2024 Jul; 8(7):491-499.
-
Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies. Arterioscler Thromb Vasc Biol. 2024 May; 44(5):1156-1164.
-
Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment. Eur J Prev Cardiol. 2024 Feb 15; 31(3):302-310.
-
Modelling the potential long-term survival benefit of evinacumab treatment vs. standard of care in patients with homozygous familial hypercholesterolaemia. Eur J Prev Cardiol. 2023 11 30; 30(17):1874-1880.
-
2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J. 2023 Jul 01; 44(25):2277-2291.
-
International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia. Nat Rev Cardiol. 2023 12; 20(12):845-869.
-
Familial hypercholesterolemia: The nexus of endothelial dysfunction and lipoprotein metabolism in COVID-19. Curr Opin Lipidol. 2023 06 01; 34(3):119-125.
-
Familial Hypercholesterolemia Identification by Machine Learning Using Lipid Profile Data Performs as Well as Clinical Diagnostic Criteria. Circ Genom Precis Med. 2022 10; 15(5):e003324.
-
Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT. Lancet Diabetes Endocrinol. 2022 10; 10(10):732-740.